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IMPORTANCE Community-based studies have linked psychotic experiences (PEs) with
increased risks of suicidal thoughts and behaviors (STBs). However, it is not known if these
associations vary across the life course or if mental disorders contribute to these associations.
OBJECTIVE To examine the temporal association between PEs and subsequent STBs across
the life span as well as the influence of mental disorders (antecedent to the STBs) on these
associations.
DESIGN, SETTING, AND PARTICIPANTS A total of 33 370 adult respondents across 19 countries
from theWorld Health OrganizationWorld Mental Health Surveys were assessed for PEs,
STBs (ie, ideation, plans, and attempts), and 21 DSM-IVmental disorders. Discrete-time
survival analysis was used to investigate the associations of PEs with subsequent onset
of STBs.
MAIN OUTCOMES ANDMEASURES Prevalence and frequency of STBs with PEs, and odds ratios
and 95% CIs.
RESULTS Of 33 370 included participants, among those with PEs (n = 2488), the lifetime
prevalence (SE) of suicidal ideation, plans, and attempts was 28.5% (1.3), 10.8% (0.7), and
10.2% (0.7), respectively. Respondents with 1 or more PEs had 2-fold increased odds of
subsequent STBs after adjusting for antecedent or interveningmental disorders (suicidal
ideation: odds ratio, 2.2; 95% CI, 1.8-2.6; suicide plans: odds ratio, 2.1; 95% CI, 1.7-2.6; and
suicide attempts: odds ratio, 1.9; 95% CI, 1.5-2.5). There were significant dose-response
relationships of number of PE types with subsequent STBs that persisted after adjustment for
mental disorders. Although PEs were significant predictors of subsequent STB onset across
all life stages, associations were strongest in individuals 12 years and younger. After
adjustment for antecedent mental disorders, the overall population attributable risk
proportions for lifetime suicidal ideation, plans, and attempts associated with temporally
prior PEs were 5.3%, 5.7%, and 4.8%, respectively.
CONCLUSIONS AND RELEVANCE Psychotic experiences are associated with elevated odds of
subsequent STBs across the life course that cannot be explained by antecedent mental
disorders. These results highlight the importance of including information about PEs in
screening instruments designed to predict STBs.
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P rior studies suggest that psychotic experiences (PEs)are associated with an elevated risk of suicidalthoughts and behaviors (STBs). A 2016 meta-analysis
by Honings et al1 based on 21 studies reported a 3-fold
increased risk of STBs in people with PEs (odds ratio
[OR], 3.2; 95% CI, 2.3-4.4). Other studies have doc-
umented a significant dose-response relationship between
the number of PEs and increased odds of STBs.2-5 Worry-
ingly, prospective studies of school-aged children have
reported strong associations between PEs and suicide
attempts, with children with PEs having an approximately
11-fold increased odds of suicide attempts during the follow-
ing 12 months (OR, 11.3; 95% CI, 4.4-28.6) compared with
those without PEs.6
Despite the growing body of evidence linking the pres-
ence of PEs with STBs, several research questions warrant
closer attention. First, there is considerable variation in
effect size estimates for these associations across studies,
likely owing to differences in methods and analysis.1,7,8
Thus, it would be informative to examine these associations
across different sites using similar methods. Second, prior
studies have documented that most common mental disor-
ders are associated with increased odds of both PEs9 and
STBs.10-12 However, it is unclear whether the presence of
mental disorders explains the associations of PEs with sub-
sequent STBs.13 Third, although it has generally been
assumed that mental disorders could increase the risk of
each of 3 main STB outcomes (ie, ideation, plans, and
attempts), recent studies have shown that only a subset of
those with ideat ion also have suic ide plans and
attempts.14-16 We examine the role of PEs with respect to the
odds of transitioning between ideation, plans, and attempts.
Fourth, there is evidence to suggest that the association
between PEs and STBs may be stronger in samples based on
children6 compared with estimates based on adult samples.1
Thus, it would be of interest to examine if the strength of the
association between PEs and STBs differed across age groups
within one study. If children and/or adolescents with PEs are
differentially prone to STBs compared with older age groups,
then this could have important clinical implications for
screening in pediatric and adolescent settings.6 Fifth, there
is considerable uncertainty about the population attribut-
able risk proportions (PARPs) for STBs that are associated
with PEs. For example, DeVylder et al16 reported that about
29% of suicide attempts were attributable to PEs among US
adults. Kelleher et al6 have found that 56% to 75% of suicide
attempts among adolescents aged 13 to 16 years were attrib-
utable to PEs (however, these estimates were imprecise; OR,
67.50; 95% CI, 11.41-399.21). Accurate and age-range specific
estimates of these PARPs are important for policy-making
and prevention purposes.
Specifically, we aimed to examine the association
between PEs (and related PE type and frequency metrics)
and subsequent STBs across the life span and the influence
of mental disorders on these associations. We also exam-
ined the associations between PEs, suicide plans and
attempts among individuals with suicidal ideation, and the
PARPs of various STBs.
Method
Samples
The data were derived from 19 WHO World Mental Health
(WMH) surveys, a coordinated set of community surveys ad-
ministered inprobabilitysamplesofadult respondents (18years
andolder) in countries throughout theworld17 (eTable 1 in the
Supplement). The weighted (by sample size) average re-
sponse rate across the 19 surveyswas 72.3%,with the highest
response rate in Iraq (95.2%) and the lowest inFrance (45.9%).
Further information on details of the procedure and the as-
sessment of mental disorders can be found in the eMethods
in the Supplement. A human subjects review board or ethics
committee approved the survey protocol in each country
(eTable 2 in the Supplement), and all respondents gave in-
formed consent; themode of consent (written vs oral) varied
by survey.
Measures
Psychotic Experiences
The Composite International Diagnostic Interview Psychosis
Module includedquestions about 6PE types—2 related tohal-
lucinatory experiences and 4 related to delusional experi-
ences. We excluded PEs experienced while dreaming, half-
asleep, or under the influence of alcohol or drugs (eTable 3A
and B in the Supplement). In this article, we present esti-
mates of STBs for “Any PEs” only (ie, not individual types of
PEs). In addition, we included 2 key PE variables: (1) number
of PE types; and (2) an annualized frequencymetric based on
the frequency of PE episodes (ie, the count of PE occurrences
per year). We derived the latter by dividing the total number
of PE episodes by the time since onset of the first PE (age at
interviewminus age at onset plus 1 in order to avoid zero as a
denominator). Age at onset of PEs was also assessed.
Suicidality
Lifetime STBs were assessed using the Composite Interna-
tional Diagnostic Interview Suicidality Module.17 Separate
questions were asked about the lifetime occurrence of sui-
cidal ideation (“Have you ever seriously thought about com-
mitting suicide?”), suicide plans (“Have you evermade a plan
forcommittingsuicide?”), andsuicideattempt (“Haveyouever
Key Points
Question Are psychotic experiences associated with subsequent
suicidal thoughts and behaviors (STBs), and domental disorders
(antecedent to the STBs) contribute to these associations?
Findings Based on 33 370 adult survey respondents drawn from
19 countries, those with psychotic experiences had 2-fold
increased odds of subsequent STBs (after adjusting for mental
disorders). Psychotic experiences were predictors of subsequent
STB onset across all life stages; however, the strength of the
association was strongest in individuals 12 years and younger.
Meaning Screening for psychotic experiences may assist in the
prediction of subsequent STBs.
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attempted suicide?”). Information on the age at first occur-
rence for each of these outcomes was obtained retrospec-
tively. Consistent with our goals of examining associations of
PEwithacontinuumof suicidalbehaviors,weconsideredeach
of these 3 primary outcomes in the total sample. In addition,
we examined 3 secondary nested STB outcomes: (1) suicide
plans among respondents with ideation; (2) suicide attempts
among those with both ideation and a plan (ie, planned at-
tempts); and (3) suicideattemptsamongrespondentswith ide-
ation but without a plan (ie, unplanned attempts).
Statistical Analysis
The predictive associations of temporally prior PEswith each
STBoutcomewereestimatedusingdiscrete-timesurvivalmod-
els,withperson-year as theunit of analysis.Aperson-yeardata
set was constructed, where each year in the life of each re-
spondent (up to and including the age of STB onset or age at
interview,whichever came first)was treated as a separate ob-
servational record, with the year of STB onset coded as 1 and
earlier years coded as 0. Psychotic experienceswere coded as
1 a year after the first PE onset to ensure that a PE occurring in
the sameyear as STBsdidnot count as a predictor.We first es-
timated models of PE and subsequent STBs adjusting for re-
spondent’s age at time of interview, sex, person-year dum-
mies, and country. In addition, we built models adjusted for
age at time of interview, sex, person-year dummies, country,
and 21 antecedentmental disorders (ie,mental disorders that
hadonsets prior to theSTBs) to examine the influenceofmen-
taldisordersontheassociationbetweenPEsandSTBs.The joint
significance test and test for linear trendwere computed.We
also conducted a post hoc analysis stratified bymental illness
(yes/no) inexaminingwhether theassociationbetweenPEsand
STBs was observed in both the groups.
Next, we reestimated the associations between PEs and
subsequent STBs after stratifying the sample into 4 life
course stages: childhood (12 years and younger), adoles-
cence (aged 13-19 years), young adulthood (aged 20-29
years), and later adulthood (30 years and older). This
allowed us to examine whether the associations varied
across the life course and the strength of association (in early
vs later years of life), given previous findings of large effect
sizes among adolescents (ORs >10).6,18 Finally, PARPS were
calculated by converting the ORs obtained from the survival
models as approximation of relative risk based on the
assumption that the survival coefficients represented causal
effects.19
As theWMHdata areboth clusteredandweighted, thede-
sign-basedTaylor series linearization implemented inSUDAAN
software (RTI International)was used to estimate the SEs and
evaluate the statistical significance of the coefficients. Sur-
vival coefficients and their SEs were exponentiated to gener-
ateORs and95%CIs. All statistical tests (Wald χ2 basedondis-
crete-timesurvivalmodels)wereevaluatedusing2-sidedtests.
Statistical significance was set at P<.05.
Results
Prevalence of STBs
The lifetimeprevalence (SE) of suicidal ideation,plans, andat-
tempts in all respondentswas 9.2% (0.2), 3.1% (0.1), and2.8%
(0.1), respectively (Table 1). Among5106 individualswith sui-
cidal ideation, 2000 (33.6%; SE, 0.9) reported a suicide plan.
Among the subset of 2000 individuals with suicidal ideation
with aplan, theprevalenceof suicide attemptswas 55.5% (SE,
1.5). Among the subset of 3106 individuals with suicidal ide-
ation without a plan, the prevalence of suicide attempts was
17.0% (SE, 0.9). (The proportions for the nested suicide out-
comes reflect different denominators; eTable 4 in the Supple-
ment.)The lifetimeprevalenceofSTBswassubstantiallyhigher
among those with PEs compared with those without PEs
(Table 1). Specifically, among respondentswithPEs, thepreva-
lence (SE) of suicidal ideation, plans, and attemptswas 28.5%
(1.3), 10.8%(0.7), and 10.2%(0.7), respectively, comparedwith
8.0% (0.2), 2.6% (0.1), and 2.3% (0.1) for respondents with-
out PEs.
Table 1. Lifetime Prevalence of Suicidal Ideation, Plans, and Attempts
Characteristic
Ideation Plans Attempts
No./Total No. (%)a SE No./Total No. (%)a SE No./Total No. (%)a SE
STB prevalence 5106/33 370 (9.2) 0.2 2000/33 370 (3.1) 0.1 1771/33 370 (2.8) 0.1
PE status
No PE 4165/30 882 (8.0) 0.2 1583/30 882 (2.6) 0.1 1388/30 882 (2.3) 0.1
Any PE 941/2488 (28.5) 1.3 417/2488 (10.8) 0.7 383/2488 (10.2) 0.7
No. of PE types (in those with PEs)
Exactly 1 PE type 571/1706 (23.8) 1.4 236/1706 (8.6) 0.7 219/1706 (8.0) 0.7
Exactly 2 PE types 247/566 (35.4) 3.4 111/566 (12.8) 1.6 98/566 (12.1) 1.6
≥3 PE types 123/216 (57.5) 4.9 70/216 (28.8) 4.2 66/216 (27.9) 4.4
PE annualized frequency metric
(in those with PEs)b
≤0.3 Episodes/y 425/1259 (25.7) 1.9 183/1259 (9.6) 1.0 167/1259 (9.0) 1.0
>0.3 Episodes/y 516/1229 (31.7) 1.8 234/1229 (12.2) 1.1 216/1229 (11.5) 1.0
Abbreviations: PE, psychotic experience; STB, suicidal thoughts and behaviors.
a Numerators refer to the number of individuals with each suicidal outcome.
Denominators refer to the number of individuals in the total sample or in the
sample of those with/without PEs. Estimates are based on weighted data.
bAnnualized PE (frequency of PE per year) = frequency of PE
occurrences / (age at interview − age of onset of PE + 1).
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Associations Between Lifetime PEs and Subsequent Onset
of STBs
Compared with those without PEs, those with any PEs had
3-fold the odds of a subsequent first onset of each STB out-
come after adjusting for demographic factors (Table 2), with
adjusted ORs for suicidal ideation, plans, and attempts of
3.0 (95% CI, 2.6-3.6), 3.4 (95% CI, 2.8-4.1), and 3.1 (95% CI,
2.4-3.9), respectively. Overall, the PE-type metric was sig-
nificant in predicting 3 STBs (χ2 ranged between 137.5 and
256.2; P < .001). The tests for linear trend were also signifi-
cant, with χ2 ranging between 15.0 and 24.7, indicating that
there was a dose-response relationship. The ORs for STBs
among those experiencing 3 or more PE types ranged from
7.1 for ideation (95% CI, 4.9-10.3) to 11.1 for plans (95% CI,
7.1-17.4). There was also a 3-fold to 4-fold increased odds of
various STBs in those with more frequent annualized PEs
(more than 0.3 episodes per year) compared with those with
less frequent annualized PEs (0.3 episodes or less per year),
with ORs ranging from 3.0 for attempts (95% CI, 2.3-4.1) to
3.8 for plans (95% CI, 2.9-5.1).
When we adjusted for 21 antecedent mental disorders,
the effect sizes attenuated but remained statistically signifi-
cant. After adjustment, those with any PEs had twice the
odds of subsequent onset of all 3 STBs. The significant dose-
response relationship between higher PE frequency metrics
and STBs also persisted.
When we restricted the analysis to the subset with sui-
cidal ideation, the associations of any PEs with suicide plans
and suicide attemptswere not significant, indicating that PEs
are associatedwith increasedoddsof suicidal ideationbutnot
with an increased odds of planning or attempting suicide
amongthose reportingsuicide ideation (eTable5 in theSupple-
ment). As a post hoc analysis, we also repeated the analysis
stratifiedbymentaldisorders (yes/no).While the95%CIswere
wider in the subgroup with no mental disorders, the general
pattern of findings persisted (eTable 6 in the Supplement).
Associations Between Lifetime PEs and Subsequent Onset
of STBs Across 4 Life Course Stages
Table3showstheassociationsbetweenPEsandsubsequenton-
set of STBs in4 life course stages. In thebasic demographic ad-
justmentmodels,we foundstrongandsignificant associations
betweenoccurrenceofPEs andsubsequentonset of STBs in all
4lifecoursestages(childhood,adolescence,earlyadulthood,and
later adulthood). The effect sizes were significantly higher in
childhoodcomparedwithotheragegroups (ideation: χ2 = 14.7;
P < .001; plans: χ2 = 17.6; P < .001; and attempts: χ2 = 8.8;
P = .003). TheORs for suicidal ideation, plans, andattempts in
childhoodwere4.0 (95%CI,2.3-6.8), 7.8 (95%CI, 3.4-17.9), and
5.4 (95%CI, 2.6-11.3), respectively.Whenadjusted for anteced-
entmental disorders, thepatternof associations remained sig-
nificant though the effect sizeswere attenuated.
Table 2. Associations Between Lifetime PEs and Subsequent Onset of Suicidal Ideation, Plans, and Attempts,With andWithout Adjustment
for AntecedentMental Disorders
Characteristic
OR (95% CI)
Ideation Plans Attempts
Basic
Demographic
Adjustmenta
Adjusted for
Antecedent
Mental Disordersb
Basic
Demographic
Adjustmenta
Adjusted for
Antecedent
Mental Disordersb
Basic
Demographic
Adjustmenta
Adjusted for
Antecedent
Mental Disordersb
PE status
Any PE 3.0 (2.6-3.6)c 2.2 (1.8-2.6)c 3.4 (2.8-4.1)c 2.1 (1.7-2.6)c 3.1 (2.4-3.9)c 1.9 (1.5-2.5)c
No. of PE types
Exactly 1 PE type 2.5 (2.0-3.1)c 1.9 (1.5-2.3)c 2.6 (2.0-3.3)c 1.8 (1.4-2.3)c 2.3 (1.7-3.2)c 1.6 (1.1-2.2)c
Exactly 2 PE types 3.7 (2.7-4.9)c 2.5 (1.8-3.3)c 3.6 (2.5-5.2)c 2.1 (1.5-3.1)c 3.3 (2.2-5.0)c 1.9 (1.2-3.0)c
≥3 PE types 7.1 (4.9-10.3)c 4.1 (2.9-5.9)c 11.1 (7.1-17.4)c 5.2 (3.1-8.7)c 10.3 (6.2-17.2)c 4.0 (2.2-7.3)c
Joint significance of the
PE type measures
χ23 256.2 112.9 203.1 63.7 137.5 30.5
P value <.001 <.001 <.001 <.001 <.001 <.001
Difference in the ORs of
the PE type measures
χ22 24.3 14.7 32.4 15.0 26.0 7.6
P value <.001 .001 <.001 .001 <.001 .02
Test for linear trend
χ21 15.0 13.2 20.6 14.3 24.7 14.6
P value <.001 <.001 <.001 <.001 <.001 <.001
PE frequency metric
>0.3 Episodes/y 3.5 (2.8-4.3)c 2.4 (2.0-3.0)c 3.8 (2.9-5.1)c 2.3 (1.7-3.0)c 3.0 (2.3-4.1)c 1.8 (1.3-2.5)c
Abbreviations: OR, odds ratio; PE, psychotic experience; STB, suicidal thoughts
and behaviors.
a Psychotic experience (any PE, number of PE type, and frequencymetric) was
used as a predictor of STB outcomes in separate discrete-time survival models.
Thesemodels control for age cohorts, sex, person-year dummies, and country.
b Thesemodels additionally control for 21 other antecedent mental disorders.
c Statistically significant at the P<.05 level (Wald χ2 based on discrete-time
survival models) using 2-sided tests.
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PARPs Between PEs and STBs
The overall PARPs for suicidal ideation, plans, and attempts
ranged between 8.4% and 11.0% (Table 4) in the basic demo-
graphic adjustment models. After adjustments for anteced-
ent mental disorders, the overall PARPs were smaller, rang-
ing from4.8% to 5.7%.Whenexamined across the life course,
comparedwitholderagegroups, children 12yearsandyounger
consistently had the highest PARPs (9.0%, 20.0%, and 11.1%
for suicidal ideation, plans, and attempts, respectively) after
adjustment for antecedent mental disorders.
Discussion
The results reported here are based on, to our knowledge, the
largest and most detailed study of PEs and STBs reported to
date.Wefoundthat community respondentswhoreportedPEs
had 2-fold increased odds of subsequent suicidal ideation,
plans, and attempts after adjustment for antecedent mental
disorders. These estimates are broadly consistent with sev-
eral longitudinal studies1,5,13,20 but slightly lower than the
pooled estimate from a 2016meta-analysis.1 We also found a
dose-response relationship between (1) higher numbers of PE
types (inkeepingwithprevious literature)2-5 and (2)higher an-
nualized PE frequency with subsequent STBs. Additionally,
these results shed new light on 4 issues. First, the association
betweenPEs andSTBspersisted after adjustment for anteced-
ent mental disorders. Second, among the subset of respon-
dents reporting suicidal ideation, PEs did not contribute sig-
nificantly to increased odds of subsequent suicide plans or
attempts. Third, the association between PEs and STBs was
most prominent in children 12 years andyounger. Fourth, PEs
accountedforanappreciableproportionofSTBs (9%-20%)dur-
ing childhood, evenwhenadjusted for antecedentmental dis-
orders. We discuss each of these in turn.
First, although the association between PEs and STBswas
attenuatedafteradjustment for21antecedentmentaldisorders,
appreciableORs(at least2-fold)werestill foundbetweenPEsand
STBs.Thesefindingareconsistentwithpreviousstudies1,3,21and
lendweight to the hypothesis that the experience of PEs, even
intheabsenceofmentaldisorders,maybesufficientto influence
thesubsequentonsetofSTBs.This isan important finding from
aclinicalpointofviewbecause it suggests thatPEsmaybeapre-
dictor of subsequent STBs even in individuals who do not
meet criteria for mental disorders. In keeping with a 2017
commentary,22wedonotpropose that thepresenceof isolated
Table 4. Population Attributable Risk Proportions of Suicidal Ideation, Plans, and Attempts Owing to Psychotic
Experiences in Each of 4 Life Course Stages,With andWithout Adjustment for AntecedentMental Disordersa
Category
Population Attributable Risk Proportions, %
Childhood
(≤12 y)
Adolescence
(Aged 13-19 y)
Young Adulthood
(Aged 20-29 y)
Later Adulthood
(≥30 y) Overall
Basic Demographic Adjustments
Ideation 14.1 10.6 9.7 8.2 8.4
Plans 27.6 13.6 11.0 8.5 11.0
Attempts 19.9 10.0 10.7 10.8 10.0
Adjusted for Antecedent Mental Disorders
Ideation 9.0 6.9 6.5 4.6 5.3
Plans 20.0 7.6 6.3 3.6 5.7
Attempts 11.1 4.8 5.5 4.3 4.8
a Population attributable risk
proportions = (p × (relative
risk − 1)) / (p × (relative
risk − 1) + 1), where p indicates the
proportion of respondents in the
sample with psychotic experiences.
Table 3. Associations Between Lifetime Psychotic Experiences and Subsequent Onset of Suicidal Ideation, Plans, and Attempts in Each
of 4 Life Course Stages,With andWithout Adjustment for AntecedentMental Disorders
Category
OR (95% CI)
Test for the
Significance of the
Slope Differences
Across 4 Life Course
Stages
Test for Significant
Differences Between
Childhood and Other
Age Groups
Childhood
(≤12 y)
Adolescence
(Aged 13-19 y)
Young Adulthood
(Aged 20-29 y)
Later Adulthood
(≥30 y) χ23 P Value χ21 P Value
Basic Demographic Adjustmentsa
Ideation 4.0 (2.3-6.8) 3.3 (2.6-4.2) 3.0 (2.3-3.9) 2.7 (2.0-3.6) 16.4 <.001 14.7 <.001
Plans 7.8 (3.4-17.9) 3.9 (2.9-5.3) 3.2 (2.3-4.5) 2.7 (1.8-3.9) 20.6 <.001 17.6 <.001
Attempts 5.4 (2.6-11.3) 3.0 (2.1-4.3) 3.1 (2.1-4.6) 3.1 (1.9-5.1) 10.8 .003 8.8 .01
Adjusted for Antecedent Mental Disordersb
Ideation 2.8 (1.5-5.0) 2.4 (1.8-3.1) 2.3 (1.8-3.0) 1.9 (1.4-2.6) 21.2 <.001 19.2 <.001
Plans 5.5 (2.2-13.8) 2.5 (1.8-3.5) 2.2 (1.6-3.1) 1.7 (1.1-2.5) 26.1 <.001 22.2 <.001
Attempts 3.2 (1.4-7.6) 1.9 (1.3-2.9) 2.0 (1.3-3.1) 1.8 (1.0-3.2) 16.5 <.001 14.0 <.001
Abbreviation: OR, odds ratio.
a Any psychotic experience was used as a predictor of suicidal thoughts and
behaviors outcomes in a discrete-time survival model controlling for age
cohorts, sex, person-year dummies, and country.
b Thesemodels additionally control for 21 other antecedent mental disorders.
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PEs is sufficient to identify individualswithanultrahigh riskof
later transition topsychoticdisorder; however, these individu-
alsdohaveanincreasedriskofarangeofotheradverseoutcomes,
includingSTBs.Psychoticexperiencesandsuicidalitymayshare
commonrisk factors (eg, traumatic lifeeventsor familyhistory).
Previous research found that the association between PEs and
STBs persisted after adjusting for trauma and experiencing
harm.3,4WehypothesizethatasPEsareassociatedwithbothpsy-
chologicaldistress23anddisability,24,25 thesefactorsmaybesuf-
ficient tocontributetotheemergenceofsubsequentSTBs.How-
ever,wenote that it is conceivable that PEs andSTBsmayboth
emergeduringaprodromalphaseof a latermentaldisorder (ie,
a disorderwith an age at onset after prior STBs). Although this
analysis isbeyondthescopeof thecurrentarticle, suchresearch
could further reinforce theclinicalutilityof routinemonitoring
ofPEsinat-risksamples.Futurestudiesmaywishtoincludemea-
sures of disorganized speech,which is a clinical feature of psy-
chotic disorder not routinely included in PE assessment.
Second, we demonstrated, to our knowledge for the first
time, that although PEs were associated with an overall in-
crease in STBs, among those with suicidal ideation, they did
not make an additional contribution to the subsequent tran-
sition tosuicideplansorplanned/unplannedattempts. Inother
words, while thosewith PEs had an increased odds of each of
the 3 STB outcomes (ie, suicidal ideation, suicide plans, and
suicideattempts), our findings suggest that thepresenceofPEs
did not alter the odds of transition from suicidal ideation to
planned or unplanned attempts. This general pattern is con-
sistent with previous research that explored the associations
of mental disorders and these nested STB outcomes.11 How-
ever, the results are in contrast toDeVylder et al,16who found
that respondentswithPEsandsuicidal ideationhadmore than
3-fold increased risk of attempting suicide. This discrepancy
may reflect differences in methods related to the use of tem-
poral ordering between the variables of interest.
Third, we found that PEs were associated with the subse-
quent onset of STBs in each of the 4 life course stages and that
thispatternof associationspersistedafter adjustment for ante-
cedentmental disorders.Mindful that PEs have awide age-at-
onset distribution (median [interquartile range], 26 [17-41]
years),26 our findings support thehypothesis thatPEsare asso-
ciatedwithan increasedoddsof subsequentSTBs regardlessof
age. However, we confirmed that the association between PEs
andSTBswas indeedmoreprominent in childhood, consistent
with previous findings based on longitudinal studies.5,6,20,27
While our studywas based on adult respondents (18 years and
older), it is reassuringtonotethatthestrongassociationbetween
childhood-onsetPEsandSTBshasbeenconfirmedinbothbroad
cross-sectionally ascertained samples, like theWMH, andpro-
spectivelystudiedadolescentcohorts.Futurestudiesmaywish
toexplorebiologicalandpsychosocial factors thatcouldexplain
whytheassociationbetweenPEsandsubsequentSTBs is stron-
ger inyoungchildrencomparedwithotheragegroups (eg,adif-
ferential sensitivity to stress28,29).
Finally, we showed that after adjustment for antecedent
mentaldisorders, theoverallPARPestimates(between4.8%and
5.7%)weresmallerthanpreviouslyreported.6,16However, inchil-
dren, the adjusted PARPs (between 9% and 20%)were similar
topreviously reportedPARPs.Werecommendcautionwhenin-
terpretingPARPs—theseestimatesassumecausalitybetweenthe
variablesof interest.19These findings lendweight to the recom-
mendationbyKelleher et al6 that clinicians should includePEs
whenassessingriskofSTBsinyoungpeopleandthatfutureclini-
calandepidemiologicstudiesofSTBsshould includePE-related
items in their risk factor battery.
Limitations
Thecurrentstudyhasseveral strengths (largesamplesize, range
ofcountries,uniformmethodsfordatacollection, temporallyor-
deredvariables, etc).However, it is important tonote the study
limitations. First, although we excluded people who were
screenedpositiveforpossiblepsychoticdisorders, theWMHsur-
veyswereadministeredby lay interviewers, andclinicalvalida-
tion of self-reported diagnoses of psychosis or mania was not
available.Second,wealsousedretrospectivereportsofageaton-
set of thePEs, STBs, andmentaldisorders; although rigorously
obtained,30 this is subject to some levelof recall bias.However,
wenote that 5prospective studieshaveconfirmed theassocia-
tionbetweenPEsandsubsequentSTBs.5,6,20,27,31Third, thesur-
veyswerecross-sectional,andwithoutadditional follow-up,we
wereunable toexamine theassociationbetweenPEsandcom-
pletedsuicide.Weareawareof2prospectivecommunity-based
studies that explored this question, but both lacked sufficient
power (ie, small number of completed suicides) to confidently
estimatethe influenceofPEsonthisoutcome.20,32Fourth, itwill
beof interest toexplore if particular typesofPEs (eg,hallucina-
tionsordelusions) aredifferentially associatedwithSTBs in fu-
ture analyses.
Conclusions
We found that PEs were independently associated with sub-
sequent STBs regardless of antecedent mental disorders.
There were significant dose-dependent relationships
between both number of PE types and annualized frequency
of PEs with subsequent STBs. The association was found at
all ages, with a stronger effect at younger ages, and were
associated with appreciable PARPs. From a public health
perspective, we speculate that the inclusion of PE items in
routine screening tools could improve the prediction of sui-
cide risk. Our study lends additional weight to the call for
the routine inclusion of PE items when assessing STBs in
both research and clinical settings.
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